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EDITORIAL
Adverse  drug  events  in  pediatric  intensive  care  are
common, but  improvement  strategies  exist
and are  effective
Eventos  adversos  a  medicamentos  em  terapia  intensiva  pediátrica  são
comuns,  mas  estratégias  de  melhoria  existem  e  são  eﬁcazes
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Off label use is associated with adverse drug
events
Pharmacotherapy  is  a  powerful  tool  to  improve  outcome  in
children,  but  there  is  still  an  obvious  need  to  reduce  drug
related  problems  through  adverse  drug  event  (ADE)  preven-
tion  and  management.1 An  ADE  can  hereby  be  deﬁned  as
‘any  harmful  and  unintended  event  resulting  from  the  use
of  a  drug  intended  for  diagnosis  or  therapy’.  Such  an  ADE
deﬁnition  is  irrespective  of  the  dose  but  more  appropriate
for  children,  since  these  patients  still  commonly  receive  off
label  drugs  using  doses  extrapolated  from  adults.  Besides  the
absence  of  labeling,  (poly)pharmacy,  inappropriate  formu-
lations,  variability  in  dosing  practices,  difﬁculties  to  assess
pharmacodynamics  effects  (e.g.  sedation,  pain),  immatu-
rity  and  organ  dysfunction  further  raise  the  risk  for  ADEs  in
critically  ill  children.2,3 In  pediatric  and  neonatal  intensive
care  units  (ICU),  off  label  use  of  drugs  is  up  to  80--90%,  so
signiﬁcantly  higher  than  the  recently  reported  30%  in  a  pri-
mary  pediatric  care  setting  in  Brazil.4 Unfortunately,  these
off  label  practices  are  associated  by  signiﬁcant  higher  risks
to  develop  ADE.  Du  et  al.  recently  quantiﬁed  this  risk  in
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license (http://creativecommons.org/licenses/by/4.0/). cohort  of  697  consecutive  PICU  admissions.5 The  overall
isk  was  13.1%,  with  an  even  higher  risk  after  cardiovascular
urgery,  during  infancy  (<1  year  of  age),  or  in  the  setting  of
olypharmacy  (≥6  drugs)  or  higher  disease  severity  (Pedi-
tric  Risk  of  Mortality  score  upon  admission).5
an we reduce the burden of adverse drug
vents?
onsequently,  we  need  strategies  to  recognize  and  pre-
ent  ADEs  in  these  populations,  and  a  clinical  pharmacy
ervice  (CPS)  may  be  a  very  effective  tool  to  do  so.  In
his  journal,  Okumura  et  al.  reported  on  their  experience
ollowing  introduction  of  a  CPS  into  a  single,  12  bed  pedi-
tric  ICU.6 Already  in  a  small  sample  of  patients  (n=53),
he  impact  of  the  CPS  on  the  detection  of  preventable  ADE
n=141  events  in  53  cases)  was  relevant.  The  most  com-
on  interventions  related  to  incompatibility  of  intravenous
olutions  (21%),  or  inadequate  doses  (17%)  and--similar  to
ther  observations1,2,5--antimicrobial  agents  were  overrep-
esented  (5  of  the  top  10  drugs)  in  the  intervention  group.This  also  means  that  such  observations  should  guide  sec-
ndary  prevention  programs  to  improve  practices:  avoid
he  avoidance,  and  learn  from  your  current  practices.  CPS
eams  of  clinical  pharmacists  should  be  an  integrated  part
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f  multidisciplinary  teams  in  addition  to  physicians,  nurses
nd  other  health  care  providers.  Clinical  pharmacists  should
rovide  beside  support  in  the  prescription  (dose,  frequency)
nd  the  administration  of  drugs  (e.g.  incompatibilities).
ecause  of  the  high  ADE  incidence,  the  ICU  environment  is
n  obvious  choice.6
ultidisciplinary teams to close the
nowledge gap
s  mentioned  earlier,  the  currently  still  too  limited
nowledge  on  pharmacotherapy  in  ICU  children  is  linked
o  a  still  too  high  incidence  of  ADEs.  Multidisciplinary
pproaches--including  clinical  pharmacists--are  very  helpful
o  reduce  preventable  ADE.  However,  we  should  not  under-
stimate  the  dynamics  of  such  multidisciplinary  teams  once
mplemented.  These  groups  can  also  generate  new  infor-
ation  on  old  drugs  (off  label  use  should  not  remain  off
nowledge)  and  they  can  develop  and  validate  best  practices
nd  new  dosing  regimens,  due  to  their  expertise  to  collabo-
ate  bedside  in  the  daily  practice  on  pharmacotherapy:  let’s
ake  things  better.
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